Pediatric Cancer Drug Supply Act of 2024
This bill aims to establish reserve supplies of essential pediatric cancer drugs by directing the Secretary of Health and Human Services to enter agreements with drug manufacturers. These agreements ensure that there is a 6-month reserve supply of each covered pediatric cancer drug held by manufacturers. The bill also emphasizes the importance of domestic manufacturing, competition, and drug quality.
Additionally, the bill includes provisions for payment terms, distribution of drugs in shortage, and reports to Congress regarding the progress of the pilot program. It defines terms such as "covered pediatric cancer drug" and "eligible source facility" to clarify the scope of the legislation.
For the implementation of this Act, an authorization of $500,000,000 for fiscal year 2024 is provided.